• by bcarlson@marketresearch.com
  • February 20 2014
  • flu vaccine


Stronger Flu Season Boosted Vaccine Revenue

Stronger Flu Season Boosted Vaccine Revenue

An upcoming report will have good news for manufacuters of flu vaccine: The lull the industry has exeprienced since 2011 may be over.  Influenza vaccines generated $3.1 billion in revenues, according to research we’ve conducted for our 2014 survey of the vaccine industry.  This is up 13.2% from the prior year on a relatively severe current flu season in the U.S., but of course it’s not like the balooning sales of ’09 or ’10.  We will make the finding in our Vaccines 2014  report  (The report is due out in April; flu data was available earlier and we are sharing with Kalorama blog readers.)  Sales in this segment had been especially strong in 2009 and 2010 due to government stockpiling - and some cases, over-purchasing - of new avian and swine flu vaccines, but have since returned to earlier levels with major flu vaccine manufacturers reporting significant declines from 2010. 

While the lower than expected demand for H1N1 vaccine will pressure future purchasing patterns to a certain extent, market growth through 2018 will be supported by new Advisory Committee on Immunization Practices (ACIP) recommendations - which will encourage vaccination, an aging global population and new products.  Older persons are a particularly important population as several worldwide pharmacoeconomic studies have shown that vaccination can prevent about 50% of deaths from influenza-related complications in the elderly.  As of early 2014, more than 900 million people worldwide were aged 55 or older and over half of these were age 65 or older.   

Look out for more notices about our new Vaccines 2014 world market report in April.  In the meantime for historic information, here is a link to our 2012 Vaccines market report.